StockNews.com upgraded shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a hold rating to a buy rating in a report released on Sunday morning. Several other analysts have also recently commented on the company. Bank of America increased their target price on Charles River Laboratories International from $235.00 to $245.00 and gave […]
Sandler Capital Management lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 77.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,237 shares of the medical research company’s stock after selling 94,163 shares during the […]
Southpoint Capital Advisors LP bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 400,000 shares of the medical research company’s stock, valued at approximately […]
Rivermont Capital Management LP bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,565 shares of the medical research company’s stock, valued at approximately $3,949,000. Charles River Laboratories International comprises 2.2% […]
Epoch Investment Partners Inc. cut its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 63.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,675 shares of the medical research company’s stock after selling 4,725 shares during the quarter. Epoch […]